Company / SG&A Expense
ALNYLAM PHARMACEUTICALS, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.2B
FY2025
5-year range
$479.0M / $1.2B
FY2021-FY2025
Trend
+24.1%
vs FY2024
Sector context
#21 of 213
Health Care
What the data says
Among 213 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the bottom 10% for sg&a expense. SG&A Expense has increased for 7 consecutive years, from $89M in FY2018 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +25.9%. Top quartile in the Health Care sector.
Increased from $796M to $1.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +27.2%
- 5-Year CAGR
- +25.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 213This company $1.2B Sector average $722.3M
▼
+67.6% above sector average
Key checks
Key Insights
- ALNYLAM PHARMACEUTICALS, INC.'s sg&a expense has grown for 7 consecutive years.
- 5-year CAGR of +25.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 24.1% year-over-year.
- Ranks #21 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +24.1% |
| FY2024 | $975.5M | +22.6% |
| FY2023 | $795.6M | +35.2% |
| FY2022 | $588.4M | +22.8% |
| FY2021 | $479.0M | +25.3% |
| FY2020 | $382.4M | +91.8% |
| FY2019 | $199.4M | +123.1% |
| FY2018 | $89.4M | -55.2% |
| FY2017 | $199.4M | +123.1% |
| FY2016 | $89.4M | +47.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026